WO1995029711A1 - Cell excluding sheath for vascular grafts - Google Patents
Cell excluding sheath for vascular grafts Download PDFInfo
- Publication number
- WO1995029711A1 WO1995029711A1 PCT/US1995/004687 US9504687W WO9529711A1 WO 1995029711 A1 WO1995029711 A1 WO 1995029711A1 US 9504687 W US9504687 W US 9504687W WO 9529711 A1 WO9529711 A1 WO 9529711A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sheath
- blood vessel
- macromolecules
- polymeric material
- microporous polymeric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
Definitions
- the present invention relates to vascular prostheses improved through the use of an external sheath that is resistant to cell ingrowth while being permeable to flux of fluid and macromolecules across the thickness of the sheath.
- the sheath can also impart mechanical strength to the vascular tissue of the prostheses.
- the practice of grafting with allogeneic arteries was abandoned in favor of the mechanically superior alternative of using vascular grafts made of synthetic materials.
- the synthetic materials principally used for this grafting are polyethylene terephthalate and expanded polytetrafluoroethylene (ePTFE). These materials offer biocompatibility and provide sufficient mechanical integrity to prevent aneurysmal dilation. Prosthetics made of these materials were shown to be successful in the replacement of large vessels such as the aorta or iliac arteries and are still successfully used in these applications. Although successful when used in large diameter applications, the patency performance of these materials in demanding small diameter applications such as coronary artery bypass or peripheral arterial bypass distal to the popliteal artery, for example, has been substantially less than that of transplanted living autologous vessels.
- Low porosity ePTFE grafts with a short fibril length (10 ⁇ m) had layers of tissue on either side of the graft wall, but no ingrowth of tissue into the interstices of the graft. These low porosity grafts were 67% patent at six months postoperatively. (Florian et al., "Small Vessel Replacement With Gore-tex (Expanded Polytetrafluoroethylene)," Arch. Surg. 111 :267-270 (1976))
- the present invention is directed to improved vascular prostheses derived from donor blood vessels. It is an object of the present invention to provide improved performance for vascular prostheses by preventing many of the failures that are a consequence of the invasion of an implant by host cells. It is a further object of the present invention to provide improved performance for vascular prostheses by providing a cell excluding covering for the vascular tissue of a prosthesis that permits exchange of biological fluids and substances across the vascular tissue of the implant and the perigraft tissue of a recipient.
- the present invention is a covering for a blood vessel which comprises a sheath surrounding the blood vessel, wherein the sheath comprises a microporous polymeric material and wherein the sheath serves as a barrier to external cellular contact to the blood vessel, while being permeable to macromolecules.
- Figure 1 is a cross-sectional view of a mammalian artery (2) having the external sheath (1) applied thereto;
- Figure 2 is another view of the embodiment of the present invention illustrated in Figure 1.
- the present invention is directed to a sheath for use in vascular prostheses derived from donor blood vessels, particularly mammalian blood vessels.
- a vascular prosthesis may employ an external sheath of the present invention around a donor blood vessel.
- the sheath prevents access to the donor vessel wall by host cells originating from perigraft tissue. While resisting host cell ingrowth, the external sheath is permeable to the flux of macromolecules across its thickness.
- the exclusion of host cells by the external sheath and the bi-directional flow of macromolecules through the external sheath assists in maintaining the original function of the underlying donor vascular tissue of the prosthesis.
- the term "macromolecules" is understood to include, but not be limited to, molecules having a molecular weight up to and including about 2,000,000 MW.
- the original architecture and function of vessel derived vascular grafts can be maintained if invasion of the donor vessel wall by host cells is prevented while the flux of macromolecules across the wall is permitted. If the original architecture and function of the arterial wall of a vascular graft is so maintained, many of the failures previously noted with transplanted vessels can be prevented, resulting in improved patency performance of these biologically derived grafts.
- the teachings of the present invention are thus directly opposite those of the prior art in this field regarding the desirability of host cell ingrowth into the donor tissue of a biological vascular graft.
- FIG. 1 A structure resembling this configuration is shown in Figures 1 and 2.
- the sheath (1) is applied to the external surface of a mammalian blood vessel (2) forming a tubular vascular graft (3).
- the flux of macromolecules across the thickness of the external sheath is achieved by constructing the sheath of materials that are permeable to macromolecules while being resistant to cell ingrowth.
- the preferred materials for construction of the external sheath are synthetic materials that are microporous.
- Suitable materials for construction of the external sheath of the present invention include, but are not limited to, the group of polymer materials with demonstrated biocompatibility and stability under implant conditions, such as, polytetrafluoroethylene (PTFE), polyethylene terepthalate, fluorinated ethylene propylene (FEP), polyethylene, polypropylene, and siloxane, for example.
- PTFE polytetrafluoroethylene
- FEP fluorinated ethylene propylene
- the external sheath employed in the preferred embodiment of the present invention is made of expanded PTFE (ePTFE) as produced in U.S. Patent 3,953,566, issued to Gore, which is incorporated herein by reference.
- the pore size that is effective in resisting cell ingrowth across the thickness of the sheath is dependent upon the thickness of the wall itself and the tortuosity of the pores connecting the outer surface with the inner surface of the sheath. In the case of regular uniform pores in a thin sheath construction (about 10-20 ⁇ m in thickness) the pores should be selected to be less than about 3 ⁇ m. This value is based upon Boyden chamber migration assays where the limit of fibroblast invasion of straight, uniform pores is about 5-8 ⁇ m and the limit of leukocyte invasion through straight, uniform pores is about 3-5 ⁇ m. (A. Albini et al., "Fibroblast Chemotaxis," Collagen Rel. Res. 5:283-296, (1985); W. Morzycki et al., "Tumor Necrosis Factor-alpha but not Interleukin-1 Induces Polymorphonuclear Leucocyte Migration Through
- Fibroblast Layers by a Fibroblast-Dependent Mechanism Immunology, 74:107-113, (1991)
- the individual pores can be somewhat larger and still serve as an effective barrier to the passage of cells across the layer.
- the pore size of the sheath is related to the fibril length of the sheath material and the thickness of the sheath material. Thicker fibrillated sheath materials generally have more tortuous pathways connecting one end of a pore to the other end of the pore.
- a thicker fibrillated sheath may have pores that are larger than invading cells, but will remain resistant to cell ingrowth due to the increased tortuosity of the pathways of the pores in thicker sheath material.
- the fibril length should be chosen to form pores that resists cellular access through the sheath, while being permeable to macromolecules.
- the fibril length of porous ePTFE that has been expanded in a single direction is defined herein as the average of ten measurements between nodes connected by fibrils in the direction of expansion.
- Ten measurements are made in the following manner. First, a photomicrograph is made of a representative portion of the sample surface, of adequate magnification to show at least five sequential fibrils within the length of the photomicrograph. Two parallel lines are drawn across the length of the photomicrograph so as to divide the photograph into three equal areas, with the lines being drawn in the direction of expansion and parallel to the direction of orientation of the fibrils.
- the fibril length is estimated by examining a representative photomicrograph of the material surface and comparing fibril lengths as described above in a manner that represents the various directional orientations of the fibrils.
- the sheath may be constructed in a tubular configuration and applied to the external surface of a stabilized artery .
- An external sheath can also be applied as a film to the outside of a donor blood vessel, and the film layers subsequently bonded together.
- the permeability characteristics of the sheath can be evaluated by testing with markers of known size, such as dextrans and polystyrene microspheres.
- dextran with an average molecular weight of about 2,000,000 MW, labelled with the colored compound fluorescein (Sigma Chemical Co., St. Louis, MO), can be used to test the ability of the sheath to pass macromolecules.
- Cell impermeability of the sheath can be tested using polystyrene microspheres with a diameter of about 3 ⁇ m (Polysciences, Inc., Wa ⁇ ington, PA) at a concentration of about 2.5% solids in suspension, for example.
- the markers are suspended as an aqueous solution or as an aqueous suspension at concentrations sufficient to provide a distinctly visible color.
- the preferred concentration of the fluorescein-labeled dextran solution is approximately 0.2 mg dextran/ml.
- the preferred concentration of the suspension of the polystyrene microspheres is approximately 0.02 ml microspheres/ml suspension, to yield about 4.5 x 107 beads/ml suspension.
- the evaluation of the sheath permeability occurs at about 23°C.
- the sheath is prepared for permeability testing by rendering it permeable to water, if necessary. For example, sheaths constructed of ePTFE are wetted with 100% ethyl alcohol and then flushed with water to remove the alcohol before permeability testing.
- the dextran test solution is instilled in the lumen of a sheath and pressurized to about 20.7 kPa using a syringe.
- the contents of the syringe are forced through the sheath and the liquid that filters through the sheath wall is collected and visually inspected against a white background for evidence of the colored dextran.
- the number of microspheres in the suspension are determined by using an appropriate counting device, such as a hemacytometer, for example.
- the permeability of the sheath is then tested by forcing the microsphere-containing suspension through the sheath material at about 20.7 kPa using a syringe.
- the syringe is refilled with water and the water also forced through the sheath at about 20.7 kPa.
- the liquid that filters through the sheath wall is collected and subjected to centrifugation at about 300 x g for about 5-10 minutes.
- the supernatant is decanted and discarded and the pellet of microspheres is resuspended in a known volume of water.
- the number of microspheres in the resuspended pellet are counted and compared with the original suspension.
- the number of microspheres that pass through the sheath are expressed as a percentage of the number introduced into the lumen of the sheath.
- An appropriate sheath for use in the present invention will pass the about 2,000,000 MW dextran at pressures at or below about 20.7 kPa so that the colored solution that filters through the sheath is clearly visible when viewed against a white background. Additionally, the sheath will not allow more than about 5% of the 3 ⁇ m microspheres to pass across its thickness at a pressure of about 20.7 kPa.
- the sheath of the present invention can also function as a component of a vascular prosthesis that supplies mechanical reinforcement for the prosthesis. While a biologic component of the graft, such as a donor blood vessel, supplies the antithrombotic properties to the vascular prosthesis, the long term mechanical stability is usually supplied by the sheath component. Accordingly, the sheath of the present invention is selected to provide mechanical strength necessary for the particular diameter of the graft used in order to resist the hoop stress induced by blood pressure, to provide sufficient mechanical strength for creating anastomoses, and to resist anastomotic stresses.
- the sheath is constructed by wrapping a mandrel with multiple layers of ePTFE film, such as those described in U.S. Patent 3,953,566 and 4,187,390, both issued to Gore, each of which is incorporated herein by reference, and adhering the film to itself by heating the film and mandrel in an oven at about 380°C for about 10 to about 20 minutes.
- the film tube is removed from the mandrel and prepared tissue graft installed in the lumen of the polymeric tube.
- Other materials, or combinations of materials may be applied to the tissue tube similarly, using temperatures and times appropriate for the physical properties of the chosen material.
- sheath material Other methods include placing a processed artery onto a mandrel and wrapping the artery with multiple layers of an ePTFE and FEP composite film, and heating the film layer very briefly from about 310°C to about 350°C to adhere the film wrap to itself on the outer surface of the vessel.
- the FEP-coated ePTFE film is made by a process which includes the steps of: a) contacting a porous PTFE substrate, usually in the form of a membrane or film, with another layer which is preferably a film of FEP or alternatively of another thermoplastic polymer; b) heating the composition obtained in step (a) to a temperature above the melting point of the thermoplastic polymer; c) stretching the heated composition of step (b) while maintaining the temperature above the melting point of the thermoplastic polymer; and d) cooling the product of step (c).
- Another sheath construction method is the fabrication of a tubular form of ePTFE constructed according to U.S. Patent 3,593,566 to Gore using a uniaxial expansion.
- the processed blood vessel is inserted into the ePTFE tube so constructed.
- the tubular form must be permeable to the passage of macromolecules but exclude the passage of cells.
- a sheath tube was constructed from a porous expanded polytetrafluoroethylene (ePTFE) film.
- ePTFE porous expanded polytetrafluoroethylene
- This porous ePTFE film had a microstructure of nodes interconnected by fibrils.
- the film was made by expansion by stretching in a single direction, which was the direction in which the resulting fibrils were primarily oriented.
- the film used in the preparation of this invention had a fibril length of about 50 ⁇ m, a density of about 0.3 g/cm, a thickness of about 0.01 mm, and were 86% porous by bulk volume.
- the fibril length of the porous ePTFE film referred to above was an estimated mean value obtained by examining a scanning electron photomicrograph of the film.
- the film was applied to a metal mandrel about 5 mm in diameter by wrapping the mandrel with the film in a helical manner.
- the pitch of the helix was such that each wrap of film overlapped approximately two-thirds of the previous wrap.
- the mandrel was wrapped three times in this fashion, resulting in a film tube constructed of about nine layers of film.
- the wrapped mandrel was then heated in a oven at about 378°C for seven minutes to adhere the film layers together.
- the mandrel was removed from the oven and allowed to cool. Once cool, the film sheath was removed from the mandrel.
- the sheath was tested for ability to pass macromolecules as follows.
- a solution of fluorescein-labeled dextran with an average molecular weight of 2,000,000 MW was prepared in water at a concentration of about 0.2 mg/ml.
- a portion of the sheath, about 10 cm in length, was mounted on a barbed Luer fitting and wetted with 100% ethyl alcohol.
- the alcohol was removed by flushing the sheath with water using a syringe to force the water through the pores of the sheath.
- the dextran test solution was instilled in the lumen of the sheath and pressurized to about 20.7 kPa.
- the contents of the syringe were forced through the sheath and the liquid that filtered through the sheath wall was collected and visually inspected against a white background for evidence of the colored dextran.
- the solution was distinctly yellow colored, and the sheath, therefore, permeable to macromolecules.
- the sheath was tested for ability to prevent cellular infiltration.
- a second 10 cm length of sheath was wetted with ethyl alcohol and the alcohol replaced with water as described above.
- Microspheres about 3 ⁇ m in diameter (Polysciences, Warrington, PA) were used to determine the ability of the sheath to prevent cellular infiltration.
- a stock suspension of microspheres was prepared. The number of microspheres in the suspension was determined to be about 4.7 x 107 spheres/ml using a hemacytometer.
- the microsphere-containing suspension was tested by forcing the contents of the syringe, 5 ml of stock suspension, through the sheath material at 20.7 kPa.
- the syringe was refilled with water and the water also forced through the sheath at 20.7 kPa.
- the liquid that filtered through the sheath wall was collected and subjected to centrifugation at about 300 x g for 5 minutes.
- the supernatant was decanted and discarded, and the pellet of microspheres was resuspended in one ml of water.
- the number of microspheres in the resuspended pellet was counted as for the original suspension and the count expressed as a percentage of the number of microspheres used for the test.
- the percentage of microspheres passing through the wall of the sheath was 0.17%.
- the sheath can be considered resistant to cell ingrowth since less than 5% of the microspheres pass through the sheath wall.
- a sheath of porous ePTFE was constructed.
- the sheath was permeable to macromolecules and resistant to cellular infiltration by the defining tests.
- the sheath can be installed onto arterial replacement grafts comprised of tissue from allogeneic or xenogeneic sources by sliding the processed artery into the lumen of the sheath.
- DMSO/HBSS Hanks' Balanced Salt Solution
- the arteries were rinsed thoroughly in HBSS and were sleeved with a 5 mm tube and pressure fixed in 0.25% glutaraldehyde in 0.020 M N- 2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid (HEPES) , pH 7.3, with 0.44% NaCl and 0.26% MgCh-6H2 ⁇ , at about 27.6 kPa for about 2 hours.
- the arteries were then removed from their sleeves and left immersed in the fixing solution overnight. After fixing, the arteries were rinsed thoroughly in normal saline and sleeved with the sheath from Example 1.
- the finished wall thickness of the sleeved digested artery was 0.14 mm while the finished wall thickness of the sleeved control artery was 0.22 mm.
- arteries Arteries of an appropriate size to provide a finished internal diameter of approximately 4 mm were selected.
- the arteries were sleeved with 5 mm GORE- TEX® Vascular Graft (W. L. Gore & Associates, Inc., Flagstaff, AZ), mounted on barbed Luer fittings and were pressure fixed at about 27.6 kPa for 2 hours in 2.5% glutaraldehyde in 0.2 M Sorenson's phosphate buffer, pH 7.0. Fixation occurred at about 23°C. After fixation, the arteries were rinsed in normal saline, and stored in normal saline at about 4°C until required for use.
- the sheath to the fixed arteries was performed as follows.
- the artery was placed onto a 3 mm diameter mandrel and the ends of the artery secured with wire ties.
- a helical wrap of 25.4 mm wide film was applied over the outer surface of the arteries.
- the film used for the helical wrapping was a porous ePTFE film with an additional layer or coating of fluorinated ethylene propylene (FEP) on one surface.
- FEP fluorinated ethylene propylene
- the FEP-coated porous ePTFE film was made by a process which comprises the steps of : a) contacting a porous ePTFE substrate, usually in the form of a membrane or film, with another layer which is preferably a film of FEP or alternatively of another thermoplastic polymer; b) heating the composition obtained in step (a) to a temperature above the melting point of the thermoplastic polymer; c) stretching the heated composition of step (b) while maintaining the temperature above the melting point of the thermoplastic polymer; and d) cooling the product of step (c).
- the FEP coating of the porous ePTFE film for this example was discontinuous, thereby resulting in a porous composite film.
- the porous FEP-coated ePTFE film used to make this example had a thickness of about 0.03 mm, a density of about 0.3 g/cc, a fibril length of about 40 ⁇ m, and a width of about 25.4 mm.
- the FEP-coated side of the film was placed against the fixed arterial tissue.
- the pitch of the helical wrap was chosen such that each wrap of the film overlapped approximately two-thirds of the prior wrap.
- the arteries were wrapped three times in this fashion, resulting in a film layer constructed from about nine layers of film.
- the film-wrapped arteries were contacted very briefly by an aluminum fixture heated to about 350°C to thermally bond the layers of film together while minimizing the heating of the fixed artery.
- the fixture was an aluminum ring with an internal diameter of about 0.8 cm, a wall thickness of about 1.5 cm and an overall length of about 5 cm.
- the process employed to bond the film layers was to place the wrapped artery through the hole in the fixture, contact the surface of the film to the heated fixture and rotate the graft assembly.
- One revolution of a graft with an outside diameter of about 5 mm was performed in 1.5 to 2.0 seconds.
- the wire ties attaching the artery to the mandrel were removed and the fixed artery with the sheath applied removed from the mandrel.
- the artery-sheath composite was stored in normal saline or water until permeability testing of the sheath could be performed.
- the sheath was removed from the artery and the artery discarded.
- the sheath was tested for ability to pass macromolecules and to prevent cellular infiltration as described in Example 1.
- the sheath when prefreated by wetted with 100% ethyl alcohol, readily passed the 2,000,000 MW dextran, indicating that a sheath constructed in this fashion was permeable to macromolecules.
- the same sheath allowed no measurable quantity of the 3 ⁇ m microspheres to pass through, indicating that this sheath construction is resistant to cellular infiltration.
- One artery of the pair was sleeved with the sheath described in Example 1. The other was unsleeved. Testing occurred at about 23°C. To test, each artery was slipped over a segment of latex tubing and one end of the tubing and graft assembly connected to a pressure source. The tubing was filled with water and the other end of the assembly clamped with a hemostat. The water pressure inside the tubing was increased at about 69 kPa/sec until the graft ruptured. The pressure at which rupture occurred was recorded.
- Permeability of the sheath of the present invention to macromolecules, while being resistant to host cell ingrowth is a necessary element in providing improved patency performance of donor blood vessels.
- permeable and impermeable sheaths were constructed from ePTFE tubing prepared as described in U.S. Patent 3,953,566, issued to Gore, which is incorporated herein by reference.
- the tubing had a mean fibril length of 5 ⁇ m, an internal diameter of about 5 mm, and a wall thickness of about 0.48 mm.
- the tubing was cut into segments about 10 cm in length. Half of the segments were rendered impermeable by wetting the tubing with 1,1,2 trichloro- 1,2,2- trifluoroethane (Freon TF, E.I. duPont de Nemours, Inc., Wilmington, DE) and infiltrating the pores of the tubing with a 50% (approximate) (v:v) mixture of 1,1,2 trichloro- 1, 2,2- trifluoroethane and Silastic Type A Medical Grade Adhesive (Dow Corning, Inc., Midland, MI).
- the tubing was then placed on a 5 mm diameter mandrel and additional unthinned adhesive was applied to the outer surface of the tubing. The tubing was placed in a forced air oven at about 100°C for approximately two hours to cure the adhesive. Both the impermeable tubing and a section of untreated ePTFE tubing were cut to 5 cm and sterilized by autoclave.
- a 6 cm length of both femoral arteries was removed and the arterial branches ligated with silk ligatures.
- Each artery was placed in 15% DMSO in HBSS and frozen in liquid nitrogen for 15 days.
- the arteries were prepared for implantation into a recipient greyhound dog by first thawing the frozen arteries.
- the arteries were rapidly thawed by immersing the freezing tubes containing the arteries in 37 ⁇ C water.
- the arteries were rinsed in saline and the adventitia trimmed.
- One end of each artery was attached to a barbed Luer fitting and the arteries sleeved with a segment of 5 mm GORE-TEX® Vascular Graft (W. L.
- the arteries were immersed in 500 ml of sterile normal saline to remove the excess glutaraldehyde, and stirred at room temperature for 15 minutes, at which time the saline was replaced with 500 ml of fresh sterile normal saline.
- the arteries were rinsed for an additional 15 minutes in the fresh sterile saline.
- the arteries were stored in fresh sterile normal saline until required for implantation.
- each fixed artery segment was placed within the lumen of one of the sterile sheaths previously prepared.
- the ends of the fixed arteries were cut flush with the ends of the sheaths.
- the composite grafts so constructed were about 5 cm in length.
- the femoral arteries of a recipient greyhound dog were surgically exposed and a segment of about 5 cm excised from both femoral arteries.
- Each graft was surgically interposed into one of the femoral arteries using end-to-end technique and a continuous suture.
- Both layers of the composite grafts were anastomosed to the host femoral arteries with CV-6 GORE-TEX® Suture (W. L. Gore & Associates, Inc., Flagstaff, AZ).
- the femoral artery replaced with a processed artery covered with the impermeable sheath was found to be occluded by duplex scanner ultrasonography. Occlusion was confirmed at 20 days postoperation with contrast arteriography.
- the remaining femoral artery replaced with a processed artery covered with a permeable sheath of the present invention was visualized using arteriography and was found to be patent.
- the fixed graft with the impermeable sheath was found occluded at 19 days after implantation, while the graft with the selectively permeable sheath of the present invention remained patent for at least 60 days, at which time the grafts were explanted and the patent graft subjected to histological studies. Histological examination of the patent graft showed the inner layers of the biologic component of the patent graft had maintained the architecture of the original donor artery.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU22928/95A AU2292895A (en) | 1994-04-29 | 1995-04-17 | Cell excluding sheath for vascular grafts |
EP95916422A EP0757561A1 (en) | 1994-04-29 | 1995-04-17 | Cell excluding sheath for vascular grafts |
JP7528270A JPH09512456A (en) | 1994-04-29 | 1995-04-17 | Cell exclusion sheath for artificial blood vessels |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/235,071 US5584876A (en) | 1994-04-29 | 1994-04-29 | Cell excluding sheath for vascular grafts |
US08/235,071 | 1994-04-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995029711A1 true WO1995029711A1 (en) | 1995-11-09 |
Family
ID=22883986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/004687 WO1995029711A1 (en) | 1994-04-29 | 1995-04-17 | Cell excluding sheath for vascular grafts |
Country Status (6)
Country | Link |
---|---|
US (1) | US5584876A (en) |
EP (1) | EP0757561A1 (en) |
JP (1) | JPH09512456A (en) |
AU (1) | AU2292895A (en) |
CA (1) | CA2186373A1 (en) |
WO (1) | WO1995029711A1 (en) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6428571B1 (en) | 1996-01-22 | 2002-08-06 | Scimed Life Systems, Inc. | Self-sealing PTFE vascular graft and manufacturing methods |
US5941908A (en) * | 1997-04-23 | 1999-08-24 | Vascular Science, Inc. | Artificial medical graft with a releasable retainer |
US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
US20050033132A1 (en) | 1997-03-04 | 2005-02-10 | Shults Mark C. | Analyte measuring device |
US8527026B2 (en) | 1997-03-04 | 2013-09-03 | Dexcom, Inc. | Device and method for determining analyte levels |
US7192450B2 (en) | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
US6254627B1 (en) * | 1997-09-23 | 2001-07-03 | Diseno Y Desarrollo Medico S.A. De C.V. | Non-thrombogenic stent jacket |
US6468300B1 (en) | 1997-09-23 | 2002-10-22 | Diseno Y Desarrollo Medico, S.A. De C.V. | Stent covered heterologous tissue |
US6371982B2 (en) | 1997-10-09 | 2002-04-16 | St. Jude Medical Cardiovascular Group, Inc. | Graft structures with compliance gradients |
US6048362A (en) * | 1998-01-12 | 2000-04-11 | St. Jude Medical Cardiovascular Group, Inc. | Fluoroscopically-visible flexible graft structures |
US6235054B1 (en) | 1998-02-27 | 2001-05-22 | St. Jude Medical Cardiovascular Group, Inc. | Grafts with suture connectors |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US20040126404A1 (en) * | 1998-08-21 | 2004-07-01 | University Of Queensland Of St. Lucia | Implant material |
ATE382378T1 (en) * | 1998-08-21 | 2008-01-15 | Univ Queensland | IMPLANT MATERIAL |
WO2000048530A1 (en) * | 1999-02-16 | 2000-08-24 | Talison Research, Inc. | Multilayer and multifunction vascular graft |
US6334868B1 (en) | 1999-10-08 | 2002-01-01 | Advanced Cardiovascular Systems, Inc. | Stent cover |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
US6761700B2 (en) | 2001-02-09 | 2004-07-13 | Orqis Medical Corporation | Extra-corporeal vascular conduit |
US7041468B2 (en) | 2001-04-02 | 2006-05-09 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
US6702857B2 (en) | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
US20030032874A1 (en) | 2001-07-27 | 2003-02-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US7613491B2 (en) | 2002-05-22 | 2009-11-03 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US9282925B2 (en) | 2002-02-12 | 2016-03-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US7828728B2 (en) | 2003-07-25 | 2010-11-09 | Dexcom, Inc. | Analyte sensor |
US8364229B2 (en) * | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US7226978B2 (en) | 2002-05-22 | 2007-06-05 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US20040126405A1 (en) * | 2002-12-30 | 2004-07-01 | Scimed Life Systems, Inc. | Engineered scaffolds for promoting growth of cells |
US7134999B2 (en) | 2003-04-04 | 2006-11-14 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
US8057537B2 (en) * | 2003-04-28 | 2011-11-15 | Kips Bay Medical, Inc. | Compliant venous graft |
US7998188B2 (en) | 2003-04-28 | 2011-08-16 | Kips Bay Medical, Inc. | Compliant blood vessel graft |
US20050131520A1 (en) * | 2003-04-28 | 2005-06-16 | Zilla Peter P. | Compliant blood vessel graft |
US7875293B2 (en) | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
JP4708342B2 (en) | 2003-07-25 | 2011-06-22 | デックスコム・インコーポレーテッド | Oxygen augmentation membrane system for use in implantable devices |
US8282549B2 (en) | 2003-12-09 | 2012-10-09 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US7761130B2 (en) | 2003-07-25 | 2010-07-20 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8423113B2 (en) | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9763609B2 (en) | 2003-07-25 | 2017-09-19 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US8060173B2 (en) | 2003-08-01 | 2011-11-15 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8761856B2 (en) | 2003-08-01 | 2014-06-24 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8845536B2 (en) | 2003-08-01 | 2014-09-30 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
US8160669B2 (en) | 2003-08-01 | 2012-04-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8676287B2 (en) | 2003-08-01 | 2014-03-18 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US20140121989A1 (en) | 2003-08-22 | 2014-05-01 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US8233959B2 (en) | 2003-08-22 | 2012-07-31 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
WO2005051170A2 (en) | 2003-11-19 | 2005-06-09 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
DE602004029092D1 (en) | 2003-12-05 | 2010-10-21 | Dexcom Inc | CALIBRATION METHODS FOR A CONTINUOUSLY WORKING ANALYTIC SENSOR |
US8532730B2 (en) | 2006-10-04 | 2013-09-10 | Dexcom, Inc. | Analyte sensor |
US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8364231B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
US7364592B2 (en) * | 2004-02-12 | 2008-04-29 | Dexcom, Inc. | Biointerface membrane with macro-and micro-architecture |
US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US8792955B2 (en) | 2004-05-03 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8277713B2 (en) | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
US7946984B2 (en) | 2004-07-13 | 2011-05-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20060016700A1 (en) | 2004-07-13 | 2006-01-26 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8886272B2 (en) | 2004-07-13 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
WO2006127694A2 (en) | 2004-07-13 | 2006-11-30 | Dexcom, Inc. | Analyte sensor |
US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8452368B2 (en) | 2004-07-13 | 2013-05-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
US7641688B2 (en) * | 2004-09-16 | 2010-01-05 | Evera Medical, Inc. | Tissue augmentation device |
US8029563B2 (en) | 2004-11-29 | 2011-10-04 | Gore Enterprise Holdings, Inc. | Implantable devices with reduced needle puncture site leakage |
US8744546B2 (en) | 2005-05-05 | 2014-06-03 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
US8060174B2 (en) | 2005-04-15 | 2011-11-15 | Dexcom, Inc. | Analyte sensing biointerface |
US8163002B2 (en) * | 2005-11-14 | 2012-04-24 | Vascular Devices Llc | Self-sealing vascular graft |
WO2007143225A2 (en) | 2006-06-07 | 2007-12-13 | Abbott Diabetes Care, Inc. | Analyte monitoring system and method |
US20200037874A1 (en) | 2007-05-18 | 2020-02-06 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
WO2008154312A1 (en) | 2007-06-08 | 2008-12-18 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US9452258B2 (en) | 2007-10-09 | 2016-09-27 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
WO2009105709A1 (en) | 2008-02-21 | 2009-08-27 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US8583204B2 (en) | 2008-03-28 | 2013-11-12 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8682408B2 (en) | 2008-03-28 | 2014-03-25 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US11730407B2 (en) | 2008-03-28 | 2023-08-22 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
EP2326944B1 (en) | 2008-09-19 | 2020-08-19 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
EP2361059B1 (en) * | 2008-11-24 | 2014-05-14 | Vascular Graft Solutions Ltd. | External stent |
DK3575796T3 (en) | 2011-04-15 | 2021-01-18 | Dexcom Inc | ADVANCED ANALYZE SENSOR CALIBRATION AND ERROR DETECTION |
US10052218B2 (en) | 2011-04-18 | 2018-08-21 | Vascular Graft Solutions Ltd. | Devices and methods for deploying implantable sleeves over blood vessels |
US9814560B2 (en) | 2013-12-05 | 2017-11-14 | W. L. Gore & Associates, Inc. | Tapered implantable device and methods for making such devices |
BR112017025950A2 (en) | 2015-06-05 | 2018-08-14 | W. L. Gore & Associates, Inc. | ? low bleed implantable prosthesis with a taper? |
US20190120785A1 (en) | 2017-10-24 | 2019-04-25 | Dexcom, Inc. | Pre-connected analyte sensors |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2033234A (en) * | 1978-10-12 | 1980-05-21 | Sumitomo Electric Industries | Tubular organic prosthesis and a process for the production thereof |
DE3918736A1 (en) * | 1989-06-08 | 1990-12-13 | Christian Dr Vallbracht | PTFE coating for metal mesh prosthesis used in artery expansion - internal and external coatings are applied to mesh and prevent thrombosis and further arterial restriction |
WO1991007145A1 (en) * | 1989-11-22 | 1991-05-30 | Indu Kapadia | Prosthetic ligament |
EP0448840A2 (en) * | 1990-02-26 | 1991-10-02 | American Cyanamid Company | Bicomponent or blended wound closure device |
WO1992022604A1 (en) * | 1991-06-14 | 1992-12-23 | W.L. Gore & Associates, Inc. | Surface modified porous expanded polytetrafluoroethylene and process for making |
WO1993018214A1 (en) * | 1992-03-13 | 1993-09-16 | Atrium Medical Corporation | Controlled porosity expanded polytetrafluoroethylene products and fabrication |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3626947A (en) * | 1970-02-19 | 1971-12-14 | Charles Howard Sparks | Method and apparatus for vein and artery reenforcement |
SE392582B (en) * | 1970-05-21 | 1977-04-04 | Gore & Ass | PROCEDURE FOR THE PREPARATION OF A POROST MATERIAL, BY EXPANDING AND STRETCHING A TETRAFLUORETENE POLYMER PREPARED IN AN PASTE-FORMING EXTENSION PROCEDURE |
US3974526A (en) * | 1973-07-06 | 1976-08-17 | Dardik Irving I | Vascular prostheses and process for producing the same |
JPS6037735B2 (en) * | 1978-10-18 | 1985-08-28 | 住友電気工業株式会社 | Artificial blood vessel |
JPH0121984B2 (en) * | 1980-07-01 | 1989-04-24 | Betsuteibetopirai Kesaranazan | |
US4482516A (en) * | 1982-09-10 | 1984-11-13 | W. L. Gore & Associates, Inc. | Process for producing a high strength porous polytetrafluoroethylene product having a coarse microstructure |
US4816339A (en) * | 1987-04-28 | 1989-03-28 | Baxter International Inc. | Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation |
US4911717A (en) * | 1987-06-18 | 1990-03-27 | Gaskill Iii Harold V | Intravasular artificial organ |
ATE111715T1 (en) * | 1988-04-21 | 1994-10-15 | Uab Research Foundation | BIOELASTOMER WITHOUT ADHESION PROPERTIES FOR USE AT THE WOUND SITE. |
US5100422A (en) * | 1989-05-26 | 1992-03-31 | Impra, Inc. | Blood vessel patch |
US5084065A (en) * | 1989-07-10 | 1992-01-28 | Corvita Corporation | Reinforced graft assembly |
US5348788A (en) * | 1991-01-30 | 1994-09-20 | Interpore Orthopaedics, Inc. | Mesh sheet with microscopic projections and holes |
US5229045A (en) * | 1991-09-18 | 1993-07-20 | Kontron Instruments Inc. | Process for making porous membranes |
US5429821A (en) * | 1992-05-29 | 1995-07-04 | The Regents Of The University Of California | Non-fibrogenic high mannuronate alginate coated transplants, processes for their manufacture, and methods for their use |
-
1994
- 1994-04-29 US US08/235,071 patent/US5584876A/en not_active Expired - Fee Related
-
1995
- 1995-04-17 CA CA002186373A patent/CA2186373A1/en not_active Abandoned
- 1995-04-17 JP JP7528270A patent/JPH09512456A/en active Pending
- 1995-04-17 AU AU22928/95A patent/AU2292895A/en not_active Abandoned
- 1995-04-17 EP EP95916422A patent/EP0757561A1/en not_active Withdrawn
- 1995-04-17 WO PCT/US1995/004687 patent/WO1995029711A1/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2033234A (en) * | 1978-10-12 | 1980-05-21 | Sumitomo Electric Industries | Tubular organic prosthesis and a process for the production thereof |
DE3918736A1 (en) * | 1989-06-08 | 1990-12-13 | Christian Dr Vallbracht | PTFE coating for metal mesh prosthesis used in artery expansion - internal and external coatings are applied to mesh and prevent thrombosis and further arterial restriction |
WO1991007145A1 (en) * | 1989-11-22 | 1991-05-30 | Indu Kapadia | Prosthetic ligament |
EP0448840A2 (en) * | 1990-02-26 | 1991-10-02 | American Cyanamid Company | Bicomponent or blended wound closure device |
WO1992022604A1 (en) * | 1991-06-14 | 1992-12-23 | W.L. Gore & Associates, Inc. | Surface modified porous expanded polytetrafluoroethylene and process for making |
WO1993018214A1 (en) * | 1992-03-13 | 1993-09-16 | Atrium Medical Corporation | Controlled porosity expanded polytetrafluoroethylene products and fabrication |
Also Published As
Publication number | Publication date |
---|---|
EP0757561A1 (en) | 1997-02-12 |
US5584876A (en) | 1996-12-17 |
CA2186373A1 (en) | 1995-11-09 |
JPH09512456A (en) | 1997-12-16 |
AU2292895A (en) | 1995-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5584876A (en) | Cell excluding sheath for vascular grafts | |
US5762600A (en) | Blood contact surfaces employing natural subendothelial matrix and methods for making and using the same | |
Badylak et al. | Small intestinal submucosa as a large diameter vascular graft in the dog | |
Conklin et al. | Development and evaluation of a novel decellularized vascular xenograft | |
US6440166B1 (en) | Multilayer and multifunction vascular graft | |
US5632776A (en) | Implantation materials | |
CA1341519C (en) | Prosthetic vascular graft | |
US4687482A (en) | Vascular prosthesis | |
Guidoin et al. | In vitro and in vivo characterization of an impervious polyester arterial prosthesis: The Gelseal Triaxial® graft | |
JP2006102533A (en) | Tubular polytetrafluoroethylene implantable prostheses | |
CA2074362A1 (en) | Implantation materials | |
Dreyer et al. | Aortic grafts of polyurethane in dogs | |
Watanabe | Microarterial prostheses of expanded polytetrafluoroethylene | |
Pourdeyhimi | Vascular grafts: Textile structures and their performance | |
Nojiri et al. | Aorta-coronary bypass grafting with heparinized vascular grafts in dogs: a preliminary study | |
Huang et al. | Cellular reaction to the Vascugraft® polyesterurethane vascular prosthesis: in vivo studies in rats | |
Marois et al. | In vivo evaluation of hydrophobic and fibrillar microporous polyetherurethane urea graft | |
US10500036B2 (en) | Tissue engineering of blood vessels | |
Galletti et al. | Long-term patency of regenerated neoaortic wall following the implant of a fully biodegradable polyurethane prosthesis: experimental lipid diet model in pigs | |
Tsuchida et al. | Healing mechanisms of high-porosity PTFE grafts: significance of transmural structure | |
Pärsson et al. | Healing characteristics of polymer-coated or collagen-treated Dacron grafts: an experimental porcine study | |
Van Der Lei et al. | Microarterial grafting into the carotid artery of the rabbit: some considerations concerning species-dependent thrombogenicity | |
Hess et al. | Three years experience with experimental implantation of fibrous polyurethane microvascular prostheses in the rat aorta | |
EP1185313B1 (en) | Expanded polytetrafluoroethylene vascular graft with increased healing response | |
Tizian et al. | Using expanded polytetrafluoroethylene for bridging arterial microvascular defects: an experimental study with evaluation in the scanning electron microscopy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2186373 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995916422 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995916422 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995916422 Country of ref document: EP |